Kazia Therapeutics and Radiomics collaborate in development of novel therapy

Liege, BE 09/11/2021— Radiomics, AI-powered imaging research organization, and Kazia Therapeutics, Australian oncology company developing innovative, high-impact drugs for cancer, announced that they have entered into a partnership to enhance imaging insights for the clinical development of EVT801.

EVT801  is a small molecule inhibitor of VEGFR3, and acts by inhibiting lymphangiogenesis, the formation of new lymphatic vessels around the tumor, without inducing hypoxia, considered one of the main causes of cancer-associated immunosuppression.

EVT801 has shown compelling evidence of activity in a wide range of preclinical cancer. The phase I study, which will involve up to 60 patients, will focus primarily on understanding its safety, tolerability, and pharmacokinetics across a range of doses. It is also designed to explore preliminary signals of clinical efficacy, and to investigate the biological activity of the drug via sophisticated biomarker analyses, including radiomics-based imaging endpoints.

“We are very excited to partner with Kazia Therapeutics in this extremely promising project, our first in Australia” - said Carlos C. Meca, CCO of Radiomics – “During the last months we have learned how Australia has developed a dynamic and innovative landscape for drug development and Kazia is certainly at the head of the curve.”

Through their strategic partnership, Kazia Therapeutics and Radiomics will explore the use of Radiomics’ advanced technology platform to quantify and characterize efficacy with increasing depth and sensitivity of treatment insights, through centralized RECIST, volumetric tumor load measurements, and lesion based analysis of imaging features such as volume, shape and texture. Radiomics will work closely with Evotec, the clinical research organization in charge of this study, and leading clinical centers, Oncopole and Centre Léon Bérard in France, to collect the required high quality data for these analysis.

“The Radiomics team brings world-leading expertise in advanced imaging endpoints. With their support, we expect to get unprecedented insights into the activity of EVT801, enriching our decision-making and accelerating development of this promising new therapy.” said James Garner, CEO of Kazia Therapeutics.

The first patient has been enrolled in November 2021 and the study is planned to last up to 3 years.

About Radiomics

Radiomics is a Belgian imaging research organization built upon the unparallel experience of its founders, pioneers of the radiomics science. Radiomics focuses on AI powered healthcare, with a unique expertise in Radiomics, Deep Learning & Federated Learning applied to oncology and other therapeutic areas. Through our proprietary advanced image analysis technology, Radiomics unravels the gold mine of hidden data information embedded in standard medical images to optimize pharmaceutical and biotech companies’ clinical trials and drug development studies and to provide clinicians with a patient-centered approach based on personalized medicine. 

About Kazia Therapeutics and EVT801

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is an Australian oncology-focused drug development company.  In April 2021, Kazia Therapeutics entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE for EVT801, a small-molecule, highly selective, inhibitor of VEGFR3, originally discovered by Sanofi.

Media contact

Fabrizia Candido
Account & PR Manager
[email protected]